Fulvestrant

Curated

← predicts response to

PIK3CA C420RSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA Q546RSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA Q546ESNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA E542KSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA E545DSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA E545GSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA E545ASNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA E545KSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA H1047LSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA H1047YSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA H1047RSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA Mutationother

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA E453VSNV

sensitivity

Curated

← predicts response to

PIK3CA E453GSNV

sensitivity

Curated

← predicts response to

PIK3CA E453DSNV

sensitivity

Curated

← predicts response to

PIK3CA E453ASNV

sensitivity

Curated

← predicts response to

PIK3CA E453QSNV

sensitivity

Curated

← predicts response to

PIK3CA E453KSNV

sensitivity

Curated

← predicts response to

PIK3CA M1043TSNV

sensitivity

Curated

← predicts response to

PIK3CA M1043ISNV

sensitivity

Curated

← predicts response to

PIK3CA M1043VSNV

sensitivity

Curated

← predicts response to

PIK3CA N345YSNV

sensitivity

Curated

← predicts response to

PIK3CA N345TSNV

sensitivity

Curated

← predicts response to

PIK3CA N345SSNV

sensitivity

Curated

← predicts response to

PIK3CA N345ISNV

sensitivity

Curated

← predicts response to

PIK3CA N345HSNV

sensitivity

Curated

← predicts response to

PIK3CA N345DSNV

sensitivity

Curated

← predicts response to

PIK3CA N345KSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049DSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049CSNV

sensitivity

Curated

← predicts response to

PIK3CA G118DSNV

sensitivity

Curated

← predicts response to

PIK3CA G106DSNV

sensitivity

Curated

← predicts response to

PIK3CA G106ASNV

sensitivity

Curated

← predicts response to

PIK3CA G106SSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049ASNV

sensitivity

Curated

← predicts response to

PIK3CA G106RSNV

sensitivity

Curated

← predicts response to

PIK3CA G106VSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049RSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049SSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546HSNV

sensitivity

Curated

← predicts response to

PIK3CA K111RSNV

sensitivity

Curated

← predicts response to

PIK3CA K111NSNV

sensitivity

Curated

← predicts response to

PIK3CA K111ESNV

sensitivity

Curated

← predicts response to

PIK3CA Q546LSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546PSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546KSNV

sensitivity

Curated

← predicts response to

PIK3CA E542VSNV

sensitivity

Curated

← predicts response to

PIK3CA E542RSNV

sensitivity

Curated

← predicts response to

PIK3CA E542GSNV

sensitivity

Curated

← predicts response to

PIK3CA E542DSNV

sensitivity

Curated

← predicts response to

PIK3CA E542ASNV

sensitivity

Curated

← predicts response to

PIK3CA E542QSNV

sensitivity

Curated

← predicts response to

PIK3CA E545RSNV

sensitivity

Curated

← predicts response to

PIK3CA E545LSNV

sensitivity

Curated

← predicts response to

PIK3CA E545VSNV

sensitivity

Curated

← predicts response to

PIK3CA E545QSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047TSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047QSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047PSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047NSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047ISNV

sensitivity

Curated

← predicts response to

PIK3CA H1047DSNV

sensitivity

Curated

← predicts response to

AKT1 Mutationother

sensitivity

Curated

← predicts response to

PTEN Mutationother

sensitivity

Curated

← predicts response to

ESR1 Mutationother

resistance

Curated

← predicts response to

RB1 Mutationother

resistance

Curated

← predicts response to

PIK3CA Mutationother

resistance

Curated

← predicts response to

CCNE1 Underexpressionexpression

sensitivity

Curated

← predicts response to

CDK6 Overexpressionexpression

resistance

—

Curated

← predicts response to

PTEN Expressionexpression

resistance

Curated

← predicts response to

PIK3CA H1047RSNV

sensitivity

Curated

← predicts response to

CDK6 Overexpressionexpression

sensitivity

—

Curated

← predicts response to

TIMP1 Overexpressionexpression

resistance

Curated

← predicts response to

FGFR1 Amplificationamplification

sensitivity

Curated

← predicts response to

ESR1 Y537SSNV

sensitivity

Curated

← predicts response to

ESR1 Y537NSNV

sensitivity

Curated

← predicts response to

ESR1 Y537CSNV

sensitivity

Curated

← predicts response to

ESR1 D538GSNV

sensitivity

Curated

← predicts response to

ESR1 L536QSNV

sensitivity

Curated

Fulvestrant targets …TARGETS1 of 1
→ targets	ESR1	—	ANTAGONIST\|DEGRADER	—	1	Curated	chembl	graph →

Fulvestrant targets …TARGETS1 of 1

→ targets

ESR1

—

ANTAGONIST|DEGRADER

—

Curated

Fulvestrant investigated for …INVESTIGATED_FOR15 of 25show all (up to 200)
→ investigated for	Malignant Breast Neoplasmcancer_family 15 source records aggregated	supports	A	Malignant Breast Neoplasm	15	Curated	civic	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family 2 source records aggregated	supports	B	Malignant Breast Neoplasm	2	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	HER2-Positive Breast Carcinomamolecular_subtype 2 source records aggregated	supports	C	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
→ investigated for	Breast Lobular Carcinomasubtype	unknown	3	Breast Lobular Carcinoma	1	Curated	chembl	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family 7 source records aggregated	supports	D	Malignant Breast Neoplasm	7	Curated	civic	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	2	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Ovarian Neoplasmsubtype	unknown	2	Ovarian Neoplasm	1	Curated	chembl	graph →
→ investigated for	Endometrioid Stromal Sarcomasubtype	unknown	2	Endometrioid Stromal Sarcoma	1	Curated	chembl	graph →
→ investigated for	Female Reproductive System Neoplasmsubtype	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
→ investigated for	Endometrial Neoplasmsubtype	unknown	2	Endometrial Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	2	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Carcinomacancer_family	unknown	2	Carcinoma	1	Curated	chembl	graph →
→ investigated for	Intraductal Carcinomahistology	unknown	2	Intraductal Carcinoma	1	Curated	chembl	graph →

Fulvestrant investigated for …INVESTIGATED_FOR15 of 25show all (up to 200)

→ investigated for

Malignant Breast Neoplasmcancer_family

15 source records aggregated

supports

Curated

→ investigated for

Malignant Breast Neoplasmcancer_family

2 source records aggregated

supports

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

Breast Neoplasmcancer_family

unknown

Breast Neoplasm

Curated

→ investigated for

HER2-Positive Breast Carcinomamolecular_subtype

2 source records aggregated

supports

Curated

→ investigated for

Breast Lobular Carcinomasubtype

unknown

Breast Lobular Carcinoma

Curated

→ investigated for

Malignant Breast Neoplasmcancer_family

7 source records aggregated

supports

Curated

→ investigated for

Lung Neoplasmcancer_family

unknown

Lung Neoplasm

Curated

→ investigated for

Ovarian Neoplasmsubtype

unknown

Ovarian Neoplasm

Curated

Endometrioid Stromal Sarcoma

→ investigated for

Endometrioid Stromal Sarcomasubtype

unknown

Curated

Female Reproductive System Neoplasm

→ investigated for

Female Reproductive System Neoplasmsubtype

unknown

Curated

→ investigated for

Endometrial Neoplasmsubtype

unknown

Endometrial Neoplasm

Curated

Lung Non-Small Cell Carcinoma

→ investigated for

Lung Non-Small Cell Carcinomasubtype

unknown

Curated

→ investigated for

Carcinomacancer_family

unknown

Carcinoma

Curated

→ investigated for

Intraductal Carcinomahistology

unknown

Intraductal Carcinoma

Curated

Fulvestrant investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 67show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 224 trials (76 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	224	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 64 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 25 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 17 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 12 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Hormone Receptor-Positive Breast Carcinoma 8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hormone Receptor-Positive Breast Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 8 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Breast Carcinomamolecular_subtype 7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Breast Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Negative Breast Carcinoma 6 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Negative Breast Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Invasive Breast Carcinoma 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Invasive Breast Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Endometrial Neoplasm 6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Endometrial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	5	Observed	clinicaltrials	graph →

Fulvestrant investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 67show all (up to 200)

→ investigated in trials for

Malignant Breast Neoplasmcancer_family

224 trials (76 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

224

Observed

→ investigated in trials for

Breast Neoplasmcancer_family

64 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Breast Neoplasm

Observed

→ investigated in trials for

Solid Neoplasm

25 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

→ investigated in trials for

Breast Carcinoma

17 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Breast Carcinoma

Observed

Malignant Ovarian Neoplasm

→ investigated in trials for

12 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Ovarian Neoplasm

Observed

→ investigated in trials for

Malignant Neoplasm

10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Neoplasm

Observed

Hormone Receptor-Positive Breast Carcinoma

→ investigated in trials for

8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hormone Receptor-Positive Breast Carcinoma

Observed

Lung Non-Small Cell Carcinoma

→ investigated in trials for

Lung Non-Small Cell Carcinomasubtype

8 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

HER2-Positive Breast Carcinomamolecular_subtype

7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

HER2-Negative Breast Carcinoma

→ investigated in trials for

6 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

HER2-Negative Breast Carcinoma

Observed

Invasive Breast Carcinoma

→ investigated in trials for

6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Invasive Breast Carcinoma

Observed

Malignant Endometrial Neoplasm

→ investigated in trials for

6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Endometrial Neoplasm

Observed

→ investigated in trials for

Ovarian Carcinoma

6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Ovarian Carcinoma

Observed

→ investigated in trials for

Adult Solid Neoplasm

5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Solid Neoplasm

Observed

Malignant Prostate Neoplasm

→ investigated in trials for

5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Prostate Neoplasm

Observed

Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2

Fulvestrant studied in …STUDIED_INderived10 of 384show all (up to 200)
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 384 trials list this drug (139 active)	—	—	Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05646862Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 384 trials list this drug (139 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · 384 trials list this drug (139 active)	—	—	Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06110793Phase 1/Phase 2 · active not recruiting A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer · 384 trials list this drug (139 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · 384 trials list this drug (139 active)	—	—	Solid Neoplasm,Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07226349Phase 1 · recruiting A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · 384 trials list this drug (139 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03643510Phase 2 · completed Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer · 384 trials list this drug (139 active)	—	—	Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06979596Phase 2 · recruiting A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) · 384 trials list this drug (139 active)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02860000Phase 2 · completed Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer · 384 trials list this drug (139 active)	—	—	Malignant Breast Neoplasm,Invasive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04224272Phase 2 · completed Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 384 trials list this drug (139 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →

Fulvestrant studied in …STUDIED_INderived10 of 384show all (up to 200)

→ studied in

NCT05564377Phase 2 · recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 384 trials list this drug (139 active)

—

Observed

→ studied in

NCT05646862Phase 3 · recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 384 trials list this drug (139 active)

—

Observed

Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1

→ studied in

NCT05867251Phase 1/Phase 2 · recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors · 384 trials list this drug (139 active)

—

Observed

→ studied in

NCT06110793Phase 1/Phase 2 · active not recruiting

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer · 384 trials list this drug (139 active)

—

Observed

Solid Neoplasm,Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma

→ studied in

NCT06120283Phase 1 · recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · 384 trials list this drug (139 active)

—

Observed

→ studied in

NCT07226349Phase 1 · recruiting

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · 384 trials list this drug (139 active)

—

Solid Neoplasm

Observed

Endometrial Adenocarcinoma

→ studied in

NCT03643510Phase 2 · completed

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer · 384 trials list this drug (139 active)

—

Observed

→ studied in

NCT06979596Phase 2 · recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) · 384 trials list this drug (139 active)

—

Malignant Neoplasm

Observed

Malignant Breast Neoplasm,Invasive Breast Carcinoma

→ studied in

NCT02860000Phase 2 · completed

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer · 384 trials list this drug (139 active)

—

Observed

→ studied in

NCT04224272Phase 2 · completed

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 384 trials list this drug (139 active)

—

Breast Neoplasm

Observed